Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT03438305
Other study ID # N-74-2017
Secondary ID
Status Not yet recruiting
Phase N/A
First received February 12, 2018
Last updated February 16, 2018
Start date March 1, 2018
Est. completion date June 1, 2018

Study information

Verified date February 2018
Source Cairo University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

Background :An important risk factor for aspiration is gastric volume, determined in large part by gastric emptying. Unfortunately, measuring gastric volume over time is not easy, and scintigraphy has remained the gold standard technique for many years. Ultrasound has progressively emerged as a useful substitute due to its reduced cost and ease of performance Objectives:Assess whether ultrasonographic measurement of antral cross sectional area (CSA) can be used reliably for the diagnosis of risk stomach which defined by a gastric content volume at risk of clinical consequences for pulmonary aspiration (i.e., presence of solid particles and/or gastric fluid volume >1.5 ml/kg) during the preoperative period in longstanding diabetic patients.

Study population :

- -Longstanding diabetic patients (group D)

- -Non diabetic patients (group N) Study Design : Prospective observational study This study will be conducted at Kasr alainy Hospital; Faculty of Medicine, Cairo University.Patients scheduled for elective operations need General Anesthesia (GA) with endotracheal intubation in theatre of general surgery Preoperative ultrasound to assess gastric residual volume then general anesthesia induction will be Modified Rapid-sequence Induction as follow; Group (D)/(N) : propofol 2-3mg/kg and fentanyl 1 µg/Kg followed by Rocuronium 0.6-1.2 mg/kg.

Suction of Gastric Contents by Nasogastric tube (18 french) will be inserted First set of analysis will be comparing preoperative US findings in 2 groups.

Second set of analysis will be finding correlation between US findings and suction volume in two groups.

Outcome parameters: To assess the residual gastric volume in longstanding diabetic patients compared to non diabetic patients.

Sample Size ; was calculated as 48 patients (24) in each group.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 48
Est. completion date June 1, 2018
Est. primary completion date June 1, 2018
Accepts healthy volunteers No
Gender All
Age group 40 Years to 60 Years
Eligibility Inclusion Criteria:

- Ages from 40 to 60 years old.

- American Society of Anesthiologist (ASA) II.

- Diabetic patients with longstanding duration(more than 6 years).

Exclusion Criteria:

- Age <40,>60 years .

- Pregnant female

- Obese patients (BMI =40)

- Patients with Gastric Intestinal Tract (GIT) diseases affect gastric emptying.

- Diabetic patients less than 6 years.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
sonar assessment of gastric volume in Diabetic patients
assessment of gastric volume in Diabetic Patients
sonar assessment of gastric volume in Non Diabetic patients
assessment of gastric volume in Non- Diabetic Patients

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Cairo University

Outcome

Type Measure Description Time frame Safety issue
Primary assessment of residual gastric volume in longstanding diabetic patients To assess the residual gastric volume in longstanding diabetic patients compared to non diabetic patients intra-operative
Secondary correlation between preoperative gastric US findings and fasting hours in both groups To correlate between preoperative gastric US findings and fasting hours in both groups to confirm delayed gastric emptying in diabetic group. intraoperative
See also
  Status Clinical Trial Phase
Completed NCT03941288 - Efficacy and Safety of Cannabidiol for Gastroparesis and Functional Dyspepsia Phase 2
Terminated NCT03285308 - A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis 01 Phase 3
Completed NCT00733551 - Evaluation of the Safety, Tolerability and Pharmacokinetics of Repeat Oral Doses of GSK962040 Administered to Healthy Adult Subjects. Phase 1
Completed NCT01650714 - Endoscopic Full Thickness Biopsy, Gastric Wall. N/A
Completed NCT01452815 - Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis Phase 2
Completed NCT01039974 - GSK962040 Drug-drug Interaction Study With Ketoconazole Phase 1
Terminated NCT04844190 - Use of EndoFLIP and Manometry Prior to G-POEM N/A
Enrolling by invitation NCT06215547 - Medtronic Enterra II Neurostimulator N/A
Completed NCT04026997 - A Phase 2 Study of CIN-102 in Adults With Idiopathic and Diabetic Gastroparesis Phase 2
Completed NCT00562848 - A Study to Evaluate Safety, Side Effects, Muscle Activity and Speed of Gastric Emptying of GSK962040 Phase 1
Enrolling by invitation NCT04207996 - Vagus Nerve Response in Gastroparesis Patients
Completed NCT04607304 - ABCA2 GIRMS Analytical Validation Clinical Performance Study N/A
Recruiting NCT06068114 - Gastric Pathophysiology in Diabetes
Completed NCT03259841 - Ultrasound Assessment of Gastric Contents in Fasted Patient Undergoing Cholecystectomy
Active, not recruiting NCT04300127 - Pioglitazone for Idiopathic Gastroparesis Early Phase 1
Recruiting NCT01696734 - Domperidone in Treating Patients With Gastrointestinal Disorders Phase 3
Terminated NCT04635306 - 13C-Spirulina Nitrogen Content GEBT Study N/A
Withdrawn NCT02420925 - Effect of Celiac Plexus Block on Gastric Emptying and Symptoms Caused by Gastroparesis N/A
Recruiting NCT00777439 - Domperidone for Refractory Gastrointestinal Disorders N/A
Terminated NCT00760461 - Domperidone in Refractory Gastroparesis Phase 2